3/27
07:15 am
avir
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients [Yahoo! Finance]
Medium
Report
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients [Yahoo! Finance]
3/27
07:00 am
avir
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients
Medium
Report
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients
2/29
10:25 am
avir
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
2/28
05:13 pm
avir
Atea Pharmaceuticals Inc (AVIR) Announces Q4 and Full Year 2023 Financial Results [Yahoo! Finance]
Low
Report
Atea Pharmaceuticals Inc (AVIR) Announces Q4 and Full Year 2023 Financial Results [Yahoo! Finance]
2/28
04:13 pm
avir
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
Low
Report
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
2/28
04:05 pm
avir
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Low
Report
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
2/21
07:00 am
avir
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024
Low
Report
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024
2/13
08:30 am
avir
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Atea Pharmaceuticals, Inc. (AVIR) and Encourages Investors to Contact the Firm
Medium
Report
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Atea Pharmaceuticals, Inc. (AVIR) and Encourages Investors to Contact the Firm
2/28/2024
04:05 pm
AVIR
atea pharmaceuticals, inc. - common stock
MISS
Report
-1.4%
atea pharmaceuticals, inc. - common stock
11/8/2023
04:05 pm
AVIR
atea pharmaceuticals, inc. - common stock
BEAT
Report
-9.1%
atea pharmaceuticals, inc. - common stock
8/8/2023
04:05 pm
AVIR
atea pharmaceuticals, inc. - common stock
BEAT
Report
3.8%
atea pharmaceuticals, inc. - common stock
5/8/2023
04:05 pm
AVIR
atea pharmaceuticals, inc. - common stock
BEAT
Report
-2.6%
atea pharmaceuticals, inc. - common stock
2/28
05:43 pm
avir
Form 10-K Atea Pharmaceuticals, For: Dec 31
Low
Report
Form 10-K Atea Pharmaceuticals, For: Dec 31
2/28
04:25 pm
avir
Form 8-K Atea Pharmaceuticals, For: Feb 28
Low
Report
Form 8-K Atea Pharmaceuticals, For: Feb 28
2/15
11:35 am
avir
Form SC 13G/A Atea Pharmaceuticals, Filed by: EcoR1 Capital, LLC
Low
Report
Form SC 13G/A Atea Pharmaceuticals, Filed by: EcoR1 Capital, LLC
2/15
09:16 am
avir
Form SC 13G/A Atea Pharmaceuticals, Filed by: EcoR1 Capital, LLC
Medium
Report
Form SC 13G/A Atea Pharmaceuticals, Filed by: EcoR1 Capital, LLC
2/14
08:03 pm
avir
Form SC 13G/A Atea Pharmaceuticals, Filed by: EcoR1 Capital, LLC
Medium
Report
Form SC 13G/A Atea Pharmaceuticals, Filed by: EcoR1 Capital, LLC
2/13
05:00 pm
avir
Form SC 13G/A Atea Pharmaceuticals, Filed by: VANGUARD GROUP INC
Medium
Report
Form SC 13G/A Atea Pharmaceuticals, Filed by: VANGUARD GROUP INC
2/13
04:30 pm
avir
Form SC 13G/A Atea Pharmaceuticals, Filed by: Sommadossi Jean-Pierre
Medium
Report
Form SC 13G/A Atea Pharmaceuticals, Filed by: Sommadossi Jean-Pierre
2/9
08:36 am
avir
Form SC 13G/A Atea Pharmaceuticals, Filed by: FMR LLC
Low
Report
Form SC 13G/A Atea Pharmaceuticals, Filed by: FMR LLC
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Order Stats
Sub-Penny
Odd lot
Avg. bid-ask spread
Avg. bid-ask size
Shares at ask/bid
Off exchange
Main News & Impact Reports
2/7
Form 425 Aviragen Therapeutics, Filed by: Aviragen Therapeutics, Inc.
20.6%
1/12
Form 8-K Aviragen Therapeutics, For: Jan 11
13.6%
11/29
Aviragen Therapeutics Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of Teslexivir (BTA074) for the Treatment of Condyloma
10.2%
1/17
Form 425 Aviragen Therapeutics, Filed by: Aviragen Therapeutics, Inc.
4.8%
11/7
Form 10-Q Aviragen Therapeutics, For: Sep 30
3.8%
2/6
Form 8-K Aviragen Therapeutics, For: Feb 06
3.3%
1/3
Form 424B3 Aviragen Therapeutics,
2.7%
2/7
Aviragen and Vaxart Amend Terms of Merger Agreement to Increase the Value for Aviragen Stockholders
2.0%
11/6
Aviragen Therapeutics, Inc. (NASDAQ: AVIR) had its "hold" rating re-affirmed by analysts at HC Wainwright.
1.8%
12/12
Form S-4 Aviragen Therapeutics,
1.7%
2/13
Form SC 13G/A Aviragen Therapeutics, Filed by: Broadfin Capital, LLC
-8.7%
2/9
BRIEF-Aviragen Adjourns Special Meeting Of Stockholders [Reuters]
-7.3%
2/1
Form 425 Aviragen Therapeutics, Filed by: Aviragen Therapeutics, Inc.
-7.1%
2/6
Aviragen Adjourns Special Meeting of Stockholders Until February 9, 2018
-6.0%
12/29
Form SC 13D Aviragen Therapeutics, Filed by: DIGIRAD CORP
-5.2%
1/29
Form DFAN14A Aviragen Therapeutics, Filed by: DIGIRAD CORP
-4.7%
1/12
Form PREC14A Aviragen Therapeutics, Filed by: DIGIRAD CORP
-4.4%
1/18
Form SC 13D/A Aviragen Therapeutics, Filed by: SC Fundamental Value Fund, L.P.
-4.3%
1/24
Form DFAN14A Aviragen Therapeutics, Filed by: DIGIRAD CORP
-3.0%
11/9
Form SC 13D/A Aviragen Therapeutics, Filed by: SC Fundamental Value Fund, L.P.
-2.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Register